Jupiter Wellness, Inc. (NASDAQ:JUPW) has concluded an asset purchase agreement with Ascent Clinical Research, Inc. through which it has acquired certain clinical assets including clinical trial research contracts worth $3 million in annual revenues for a purchase price of 5% royalties on future net revenues generated by the assets.
"This strategic asset purchase agreement adds immediate revenues to Jupiter in Q2 2022 and contributes positively towards EBITDA with no upfront cash or stock acquisition cost to our company. The acquired contracts and related assets enhance Jupiter's position as a research and development powerhouse while allowing us to enter the lucrative clinical research organization business," stated Jupiter CEO Brian John.
Photo: Courtesy of Jupiter Wellness, Inc.
Related News
Jupiter Wellness To Dividend SRM Entertainment Subsidiary To Its Stockholders
The Link Between Cannabis Consumption and Sleep — Cannabis Daily December 10, 2021
